Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Eklira

- PMLiVE

Novartis, Boehringer stake claims to combination COPD market

Includes combination follow-up to Spiriva

- PMLiVE

GSK clear to launch COPD hope Anoro in Europe

Strengthens respiratory platform ahead of patent expiry for Advair/Seretide

Oncology drugs under AMNOG: part one

Segmentation and comparator choice - lessons for cancer drug market access in Germany

- PMLiVE

GSK’s COPD drug Incruse cleared in Europe

Medicine is GSK’s first long-acting muscarinic antagonist

german flag

Boehringer criticises German drug price freeze

And repeats demand for update of HTA system

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

GSK’s Anoro backed in Europe for COPD

CHMP recommendation set to expand pharma company’s respiratory portfolio

Interview: Beate Wieseler, IQWIG

Head of the department of drug assessment at the German HTA body on taking a pragmatic approach to comparing medicines

- PMLiVE

GSK’s Anoro first LAMA/LABA approved for COPD in US

Important step towards eventually replacing Seretide/Advair sales

- PMLiVE

Almirall expands in US via $400m deal to buy Aqua

Will boost its standing in dermatology

- PMLiVE

IQWiG: Key data missing from public trial reports

German HTA body claims drug studies published in journals contain ”insufficient information"

Novartis day

Novartis’ combo COPD inhaler cleared in EU

Becomes first dual action bronchodilator approved in EU for COPD

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links